Bull & Bear

Bull and Bear

Verdict: Watchlist — the bull math is real (cheapest peer, highest ROE, growing fastest), but the bear has admitted accounting weaknesses sitting in the exact line where active class actions allege inflation, and management itself flagged that the Q1 2026 trading windfall will not persist. Both legs of the long thesis — multiple compression and earnings durability — face a single, dated test: the Q2 2026 print in August 2026, when the FY25 trading-income comp gets harder and any new adjusting item or estimate cut would re-widen the discount the bull says is structural. The right move is to wait for that test rather than re-litigate it. The single tension carrying this verdict is whether FY2025's +27% consolidated revenue growth (against NII -33%) is diversification proof or a trading-income windfall in diversification clothing — the same number that drives both the bull's compounding-franchise narrative and the bear's "priced-for-permanence-at-the-top" warning.

Bull Case

Bull scenario value: ~$80 (≈42% above $56.51) over a 12–18 month horizon on 14.5x forward P/E applied to FY2026E EPS of ~$5.50 — splitting the multiple gap halfway between today's 12.8x and SNEX's 17.1x. What would confirm it: Q2 2026 earnings (August 2026) printing Adjusted PBT margin above 21%, Agency & Execution margin above 25%, and another sequential rise in average clearing balances — evidence the Q1 2026 run-rate is not a one-quarter windfall. What would refute it: comp/revenue ratio rising above 63% in any quarter, a single-event clearing credit loss above $100M, or a financial-statement restatement tied to the active US securities class actions.

Bear Case

Bear scenario value: ~$34 (≈40% below $56.51) over a 12–18 month horizon via trailing P/E compression to ~8x applied to a normalised FY2026 EPS of ~$4.25 (trading reverts halfway toward FY2024, NII continues its -20% glidepath, comp holds at 61%). Cross-check: 2.2x P/B on FY2025 BVPS of $15.32 = $34. What would trigger it: Q2 2026 earnings (August 2026) — first quarter where the FY25 trading comp gets harder and the Q1 2026 vol windfall does not repeat; a consensus PBT miss or any new adjusting item that re-widens the Adj-vs-GAAP EPS gap (currently 3.4%) would force estimate cuts. What would cover it: a clean SOX 404(b) auditor attestation in the FY2026 20-F that both material weaknesses are remediated AND dismissal of the consolidated securities class action at the pleadings stage without restatement.

The Real Debate

Verdict

Watchlist. The bear carries more weight today, but only by a margin the calendar will resolve quickly. The decisive tension is whether FY2025's +27% revenue with NII -33% is the diversification thesis printing or a trading-income windfall flattering a fixed-cost income statement — and management itself put a "do not expect to persist" caveat on the Q1 2026 print the bull cites as confirmation. The bull case is genuinely strong: cheapest peer in the cohort with the highest ROE and fastest growth, a float that compounded through a rate-cut year, and clear operating leverage from a 61% comp ratio that hasn't budged in three years — a clean Q2 2026 with normalised trading and another step-up in clearing balances would compress the multiple toward SNEX, not toward TCAP. But two unremediated material weaknesses sitting on the exact balance-sheet population where seven plaintiff firms allege off-book intercompany inflation — across the IPO period itself — is the kind of overhang that deserves to be priced before it resolves, not after. The view flips to Lean Long on a clean Q2 2026 print (Adjusted PBT margin holding above 21% on a moderating trading line) combined with either remediation of one of the two material weaknesses or pleadings-stage progress on the consolidated class action; it flips to Avoid on any restatement, any single clearing credit event above $100M, or a Q2 2026 comp ratio rising above 63%.